JP2004536857A - 癌の治療のための方法及び組成物 - Google Patents
癌の治療のための方法及び組成物 Download PDFInfo
- Publication number
- JP2004536857A JP2004536857A JP2003513564A JP2003513564A JP2004536857A JP 2004536857 A JP2004536857 A JP 2004536857A JP 2003513564 A JP2003513564 A JP 2003513564A JP 2003513564 A JP2003513564 A JP 2003513564A JP 2004536857 A JP2004536857 A JP 2004536857A
- Authority
- JP
- Japan
- Prior art keywords
- oil
- composition
- group
- lipid
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 63
- 238000000034 method Methods 0.000 title claims abstract description 34
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 238000011282 treatment Methods 0.000 title claims description 34
- 201000011510 cancer Diseases 0.000 title description 10
- -1 riminophenazine compound Chemical class 0.000 claims abstract description 35
- 150000002632 lipids Chemical class 0.000 claims abstract description 31
- 150000001875 compounds Chemical class 0.000 claims abstract description 28
- WDQPAMHFFCXSNU-BGABXYSRSA-N clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 claims description 67
- 229960004287 clofazimine Drugs 0.000 claims description 66
- 239000003921 oil Substances 0.000 claims description 59
- 235000019198 oils Nutrition 0.000 claims description 59
- 208000014018 liver neoplasm Diseases 0.000 claims description 32
- 201000007270 liver cancer Diseases 0.000 claims description 27
- 210000004185 liver Anatomy 0.000 claims description 24
- 125000005843 halogen group Chemical group 0.000 claims description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 10
- 239000000194 fatty acid Substances 0.000 claims description 10
- 229930195729 fatty acid Natural products 0.000 claims description 10
- 125000005936 piperidyl group Chemical group 0.000 claims description 10
- 206010009944 Colon cancer Diseases 0.000 claims description 7
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 7
- 210000001367 artery Anatomy 0.000 claims description 7
- 210000002767 hepatic artery Anatomy 0.000 claims description 7
- 210000000056 organ Anatomy 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 150000003626 triacylglycerols Chemical class 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 235000019483 Peanut oil Nutrition 0.000 claims description 5
- 235000019498 Walnut oil Nutrition 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 229940057917 medium chain triglycerides Drugs 0.000 claims description 5
- 239000000312 peanut oil Substances 0.000 claims description 5
- 239000003549 soybean oil Substances 0.000 claims description 5
- 235000012424 soybean oil Nutrition 0.000 claims description 5
- 239000008170 walnut oil Substances 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 125000004981 cycloalkylmethyl group Chemical group 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 239000002207 metabolite Substances 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010027476 Metastases Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 239000004006 olive oil Substances 0.000 claims description 3
- 235000008390 olive oil Nutrition 0.000 claims description 3
- 208000011571 secondary malignant neoplasm Diseases 0.000 claims description 3
- 238000001802 infusion Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- FMMOOAYVCKXGMF-MURFETPASA-N ethyl linoleate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC FMMOOAYVCKXGMF-MURFETPASA-N 0.000 claims 2
- 229940031016 ethyl linoleate Drugs 0.000 claims 2
- FMMOOAYVCKXGMF-UHFFFAOYSA-N linoleic acid ethyl ester Natural products CCCCCC=CCC=CCCCCCCCC(=O)OCC FMMOOAYVCKXGMF-UHFFFAOYSA-N 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 70
- 229940079593 drug Drugs 0.000 description 33
- 239000003814 drug Substances 0.000 description 33
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 23
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 19
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 17
- 238000000338 in vitro Methods 0.000 description 16
- 230000000694 effects Effects 0.000 description 13
- 239000002609 medium Substances 0.000 description 13
- 241001529936 Murinae Species 0.000 description 12
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 10
- 238000010348 incorporation Methods 0.000 description 9
- 206010019695 Hepatic neoplasm Diseases 0.000 description 8
- 230000000717 retained effect Effects 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 238000013268 sustained release Methods 0.000 description 5
- 239000012730 sustained-release form Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 229940104230 thymidine Drugs 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 4
- 230000001028 anti-proliverative effect Effects 0.000 description 4
- 125000004494 ethyl ester group Chemical group 0.000 description 4
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 description 3
- 206010024229 Leprosy Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 229960005084 calcitriol Drugs 0.000 description 3
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 125000003636 chemical group Chemical group 0.000 description 3
- WDQPAMHFFCXSNU-UHFFFAOYSA-N clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=NC(C)C)C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-UHFFFAOYSA-N 0.000 description 3
- 239000008157 edible vegetable oil Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000010491 poppyseed oil Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 0 *c(cc1)cc(N=C2C=C3Nc4ccccc4)c1N(c1ccccc1)C2=CC3=* Chemical compound *c(cc1)cc(N=C2C=C3Nc4ccccc4)c1N(c1ccccc1)C2=CC3=* 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 206010015548 Euthanasia Diseases 0.000 description 2
- 241000207836 Olea <angiosperm> Species 0.000 description 2
- 235000019485 Safflower oil Nutrition 0.000 description 2
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000001045 blue dye Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012847 fine chemical Substances 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 235000005713 safflower oil Nutrition 0.000 description 2
- 239000003813 safflower oil Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 102100037611 Lysophospholipase Human genes 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 208000012896 Peritoneal disease Diseases 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001355 anti-mycobacterial effect Effects 0.000 description 1
- 230000002365 anti-tubercular Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 229940124447 delivery agent Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006359 hepatoblastoma Diseases 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000000062 kidney sarcoma Diseases 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000010110 radioembolization Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPR6443A AUPR644301A0 (en) | 2001-07-17 | 2001-07-17 | Method and composition for treatment of cancer |
| PCT/AU2002/000954 WO2003007957A1 (en) | 2001-07-17 | 2002-07-16 | Method and composition for treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004536857A true JP2004536857A (ja) | 2004-12-09 |
| JP2004536857A5 JP2004536857A5 (enExample) | 2006-01-05 |
Family
ID=3830401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003513564A Withdrawn JP2004536857A (ja) | 2001-07-17 | 2002-07-16 | 癌の治療のための方法及び組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20040067952A1 (enExample) |
| EP (1) | EP1423118A4 (enExample) |
| JP (1) | JP2004536857A (enExample) |
| KR (1) | KR20040038984A (enExample) |
| CN (1) | CN1551771A (enExample) |
| AU (1) | AUPR644301A0 (enExample) |
| BR (1) | BR0211436A (enExample) |
| CA (1) | CA2453993A1 (enExample) |
| MX (1) | MXPA04000518A (enExample) |
| WO (1) | WO2003007957A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018533560A (ja) * | 2015-10-06 | 2018-11-15 | レッド ヒル バイオファーマ リミテッドＲｅｄＨｉｌｌ Ｂｉｏｐｈａｒｍａ Ｌｔｄ． | 癌を治療するための併用療法 |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4763681B2 (ja) * | 2004-03-05 | 2011-08-31 | ベニテック インコーポレイテッド | ＲＮＡｉ作用媒介物の同時デリバリーのためのマルチプロモーター発現カセット |
| EP2200613B1 (en) | 2007-09-21 | 2018-09-05 | The Johns Hopkins University | Phenazine derivatives and uses thereof |
| KR20140051555A (ko) * | 2012-10-23 | 2014-05-02 | 씨지케이바이오 주식회사 | 전립선암 예방 및 치료용 약학 조성물 |
| CN103360329B (zh) * | 2013-07-18 | 2015-11-18 | 中国科学院南海海洋研究所 | 一类吩嗪化合物及其在制备抗肿瘤药物中的应用 |
| WO2019060409A1 (en) * | 2017-09-19 | 2019-03-28 | The Cleveland Clinic Foundation | INHIBITION OF CONNEXIN 46 TO TREAT A GLIOBLASTOMA AND OTHER STATES |
| CN119564691A (zh) * | 2024-12-13 | 2025-03-07 | 首都医科大学附属北京佑安医院 | 氯法齐明在制备治疗癌症的药物中的应用 |
| CN119700770A (zh) * | 2025-01-09 | 2025-03-28 | 首都医科大学附属北京佑安医院 | 氯法齐明在制备修复肠黏膜或改善肠道菌群药物中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3658M (fr) * | 1964-02-18 | 1965-11-02 | Michel Marie Andre Guerbet | Composition huileuse pour l'injection intravasculaire. |
| US4578391A (en) * | 1982-01-20 | 1986-03-25 | Yamanouchi Pharmaceutical Co., Ltd. | Oily compositions of antitumor drugs |
| JPS6296A (ja) * | 1985-03-06 | 1987-01-06 | Sumitomo Pharmaceut Co Ltd | 脂溶性白金（２）錯体 |
| EP0280741B1 (en) * | 1986-08-29 | 1994-12-07 | Kyowa Hakko Kogyo Kabushiki Kaisha | Mitomycin derivatives |
| ZA928419B (en) * | 1991-11-29 | 1994-03-01 | Univ Pretoria | Pharmaceutical substances or compositions and their use |
| US5763443A (en) * | 1994-04-05 | 1998-06-09 | Universiteit Van Pretoria | MDR resistance treatment and novel pharmaceutically active riminophenazines |
| DE69528103T2 (de) * | 1994-04-05 | 2003-05-15 | Universiteit Van Pretoria, Gauteng | Verwendung von Riminophenazin zur Behandlung von MDR-Resistenz |
| DE19843223A1 (de) * | 1998-09-22 | 2000-03-30 | Hassan Jomaa | Phosphororganische Verbindungen und ihre Verwendung |
| AUPP332898A0 (en) * | 1998-05-04 | 1998-05-28 | Unisearch Limited | Pharmaceutical composition |
-
2001
- 2001-07-17 AU AUPR6443A patent/AUPR644301A0/en not_active Abandoned
-
2002
- 2002-07-16 CA CA002453993A patent/CA2453993A1/en not_active Abandoned
- 2002-07-16 KR KR10-2004-7000795A patent/KR20040038984A/ko not_active Withdrawn
- 2002-07-16 JP JP2003513564A patent/JP2004536857A/ja not_active Withdrawn
- 2002-07-16 EP EP02748440A patent/EP1423118A4/en not_active Withdrawn
- 2002-07-16 MX MXPA04000518A patent/MXPA04000518A/es unknown
- 2002-07-16 WO PCT/AU2002/000954 patent/WO2003007957A1/en not_active Ceased
- 2002-07-16 CN CNA028157109A patent/CN1551771A/zh active Pending
- 2002-07-16 US US10/467,618 patent/US20040067952A1/en not_active Abandoned
- 2002-07-16 BR BR0211436-4A patent/BR0211436A/pt not_active IP Right Cessation
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018533560A (ja) * | 2015-10-06 | 2018-11-15 | レッド ヒル バイオファーマ リミテッドＲｅｄＨｉｌｌ Ｂｉｏｐｈａｒｍａ Ｌｔｄ． | 癌を治療するための併用療法 |
| US10946000B2 (en) | 2015-10-06 | 2021-03-16 | Redhill Biopharma Ltd. | Method for treating cancer with combination therapy |
| US11633385B2 (en) | 2015-10-06 | 2023-04-25 | Redhill Biopharma Ltd. | Combination compositions for treatment of cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1423118A1 (en) | 2004-06-02 |
| CN1551771A (zh) | 2004-12-01 |
| BR0211436A (pt) | 2004-07-13 |
| US20040067952A1 (en) | 2004-04-08 |
| EP1423118A4 (en) | 2006-03-22 |
| WO2003007957A1 (en) | 2003-01-30 |
| KR20040038984A (ko) | 2004-05-08 |
| CA2453993A1 (en) | 2003-01-30 |
| AUPR644301A0 (en) | 2001-08-09 |
| MXPA04000518A (es) | 2005-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5998137B2 (ja) | 前立腺癌を処置するための併用療法 | |
| JP5523638B2 (ja) | 化学療法用の抗腫瘍薬物を充填したナノ粒子 | |
| JP7001599B2 (ja) | 急性骨髄性白血病の処置のためのダクチノマイシン組成物および方法 | |
| RU2283105C2 (ru) | Аналоги жирных кислот для лечения рака | |
| CN108815160A (zh) | 一种雷帕霉素脂质体纳米粒及其制备方法 | |
| KR20130118981A (ko) | 다형 교모세포종의 치료를 위한 마시텐탄 포함 조합물 | |
| JP2004536857A (ja) | 癌の治療のための方法及び組成物 | |
| Ringel et al. | Cytotoxic activity of 2′, 2′-difluorodeoxycytidine (gemcitabine) in poorly differentiated thyroid carcinoma cells | |
| JP2025015727A (ja) | ｐ－ボロノフェニルアラニンを含有する注射液剤 | |
| KR20010052305A (ko) | 약제 조성물 | |
| Pourgholami et al. | Regression of Novikoff rat hepatocellular carcinoma following locoregional administration of a novel formulation of clofazimine in lipiodol | |
| CN101601669B (zh) | 用于治疗肿瘤的联合用药物 | |
| AU2002318983A1 (en) | Mathod and composition for treatment of cancer | |
| WO2021049519A1 (ja) | ｐ－ボロノフェニルアラニンを含有する注射液剤の析出防止方法 | |
| TWI905111B (zh) | 含有對硼苯基丙胺酸之注射液劑 | |
| EP2056839A1 (en) | Combination approaches to cancer treatment | |
| EP0717625A1 (en) | A method of treating liver disease and like indications with vasodilating agents | |
| AU7647294A (en) | A method of treating liver disease and like indications with vasodilating agents | |
| HK1070280A (en) | Method and composition for treatment of cancer | |
| Park et al. | Levodopa response after unilateral Pallidotomy in advanced Parkinson′ s disease | |
| Kim et al. | Preparation of WGA lectin-conjugated ellagitannin and its application | |
| Park et al. | Crystal Structure of Probucol, an Antihyperlipidemic Agent | |
| Jeong et al. | Effects of difructose anhydrides on the accumulation and disposition of iron in rats | |
| Bak et al. | Charge Transfer Complexes Photosensitize the Activation of Molecular Oxygen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050708 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050708 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20070315 |